February 2nd 2023
Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
January 26th 2023
Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.
A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.
January 19th 2023
Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.
Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.
January 12th 2023
Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.
A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.
January 5th 2023
Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.
Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.
December 23rd 2022
Stephen T. Oh, MD, PhD, discusses the anemia benefit of pacritinib in patients with myelofibrosis.
December 22nd 2022
Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.
Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.
December 21st 2022
Dr Stephen Oh reviews the use of pacritinib in patients with myelofibrosis and the impact on anemia. Funding supported by CTI Biopharma. Content independently developed by OncLive.
December 19th 2022
Stephen T. Oh, MD, PhD, discusses the benefits of pacritinib in patients with myelofibrosis.
October 19th 2022
Dr Oh reviews data assessing the impact of pacritinib on anemia in patients from the PERSIST-2 trial. Funding supported by CTI BioPharma. Content independently developed by OncLive.
June 23rd 2022
Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.
June 16th 2022
Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.
A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.
June 9th 2022
Expert perspectives on monitoring patients receiving therapy for myelofibrosis, with additional considerations for when it is appropriate to switch therapy.
Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.